Literature DB >> 26919051

Assessing cognitive impairment in patients with schizophrenia.

S Charles Schulz1, Aimee Murray.   

Abstract

Schizophrenia has existed as a distinct disorder for nearly a century, and, ever since this disorder was first described and studied, cognitive impairment has been recognized as a prominent feature. However, the positive symptoms of schizophrenia moved to the forefront of clinical and research attention in the latter half of the twentieth century. With the new movement toward functional recovery in schizophrenia, cognitive dysfunction has become an important treatment target. This shift in focus has been prompted by our evolving knowledge of brain changes associated with schizophrenia and by the mounting body of evidence indicating that cognition is closely related to functional outcome. Cognitive assessments can enhance the evaluation and treatment of all patients with schizophrenia, and clinicians may select from a variety of valid and reliable scales and assessment measures. © Copyright 2016 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 26919051     DOI: 10.4088/JCP.14074su1c.01

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

1.  Addressing Cognitive Deficits in Schizophrenia: Toward a Neurobiologically Informed Approach.

Authors:  Ashley E Walker; Jerrod D Spring; Michael J Travis
Journal:  Biol Psychiatry       Date:  2017-01-01       Impact factor: 13.382

2.  The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains.

Authors:  Verônica M Saia-Cereda; Aline G Santana; Andrea Schmitt; Peter Falkai; Daniel Martins-de-Souza
Journal:  Mol Neuropsychiatry       Date:  2017-06-17

Review 3.  Clozapine as a Model for Antipsychotic Development.

Authors:  Frederick C Nucifora; Marina Mihaljevic; Brian J Lee; Akira Sawa
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

4.  Neurocognitive profiles in the prodrome to psychosis in NAPLS-1.

Authors:  Eva Velthorst; Eric C Meyer; Anthony J Giuliano; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Larry J Seidman
Journal:  Schizophr Res       Date:  2018-08-02       Impact factor: 4.939

5.  Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist-physician collaboration in the outpatient department.

Authors:  Thanompong Sathienluckana; Weerapon Unaharassamee; Chuthamanee Suthisisang; Orabhorn Suanchang; Thanarat Suansanae
Journal:  Integr Pharm Res Pract       Date:  2018-10-26

Review 6.  Beyond NMDA Receptors: Homeostasis at the Glutamate Tripartite Synapse and Its Contributions to Cognitive Dysfunction in Schizophrenia.

Authors:  Hagar Bauminger; Inna Gaisler-Salomon
Journal:  Int J Mol Sci       Date:  2022-08-03       Impact factor: 6.208

7.  Low-dose clozapine-related seizure: A case report and literature review.

Authors:  Dan-Sheng Le; Heng Su; Zheng-Luan Liao; En-Yan Yu
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.